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Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily involving the
synovium. Evidence in recent years has suggested that the bone marrow (BM) may be involved, and may even be
the initiating site of the disease. Abnormalities in haemopoietic stem cells’ (HSC) survival, proliferation and aging
have been described in patients affected by RA and ascribed to abnormal support by the BM microenvironment.
Mesenchymal stem cells (MSC) and their progeny constitute important components of the BM niche. In this study
we test the hypothesis that the onset of inflammatory arthritis is associated with altered self-renewal and
differentiation of bone marrow MSC, which alters the composition of the BM microenvironment.
Methods: We have used Balb/C Interleukin-1 receptor antagonist knock-out mice, which spontaneously develop
RA-like disease in 100% of mice by 20 weeks of age to determine the number of mesenchymal progenitors and
their differentiated progeny before, at the start and with progression of the disease.
Results: We showed a decrease in the number of mesenchymal progenitors with adipogenic potential and
decreased bone marrow adipogenesis before disease onset. This is associated with a decrease in
osteoclastogenesis. Moreover, at the onset of disease a significant increase in all mesenchymal progenitors is
observed together with a block in their differentiation to osteoblasts. This is associated with accelerated bone loss.
Conclusions: Significant changes occur in the BM niche with the establishment and progression of RA-like disease.
Those changes may be responsible for aspects of the disease, including the advance of osteoporosis. An
understanding of the molecular mechanisms leading to those changes may lead to new strategies for therapeutic
intervention.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterised by chronic disruptive polyarthritis.
There is no cure for RA and today’s treatments aim at
achieving the lowest possible level of arthritis disease
activity. In the UK alone RA costs the health system
around £560 million a year, and £1.8 billion a year in
absence from work. The events preceding the disease
and leading to its initiation and progression are
unknown. Thus, an understanding of these processes is
crucial for the identification of new and more cost-
effective treatments and for the move from a manage-
able to a curable disease.
Although the main disease site is the synovium, there
is growing evidence that the bone marrow (BM) is
actively involved and may even be the primary initiating
site of the disease [1]. Abnormalities in both the haemo-
poietic progenitor cells and the BM stroma have been
described [2]. Patients with active RA have been seen to
exhibit low frequency and accelerated apoptosis of BM
CD34+ cells and defective clonogenic potential [2]. Dif-
ficulties in haemopoietic stem cell (HSC) transplantation
with very common, but unfortunately, relatively short-
lived responses have been reported [3]. Moreover, age-
inappropriate shortening of telomeres in CD4 T cells
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and granulocytes have been shown not only in patients
affected by RA but also in healthy adult HLA-DR4
donors, the HLA haplotype with the major genetic risk
factor for RA [4]. These data suggest that HSC undergo
increased replicative stress not only in patients affected
by RA but also in patients predisposed to RA and it can
occur independently of the rheumatoid disease process.
The causes of the increased apoptosis and replicative
stress of HSC in patients affected by RA are unknown.
HSC requires a balanced supportive environment, the
niche, to survive, proliferate and appropriately differenti-
ate. An impaired hematopoiesis-supporting capacity of
BM stroma has been described in RA patients [2]. How-
ever, it is unknown what the changes are in the bone mar-
row (BM) niche, which may lead to ineffective support of
HSC. Mesenchymal stem cells (MSCs), and their differen-
tiated progenies, including osteoblasts and adipocytes,
have been shown to be important elements of the BM
niche and have a role in HSC survival, proliferation and
differentiation [5-8]. Cells with properties of MSC have
been found to increase in the synovium of patients
affected by RA and are thought to be one of the main
causes of perpetuation of the disease, suggesting a possible
dysregulation of MSC proliferative capacity [9]. In this
study, we hypothesize that bone marrow MSCs undergo
enhanced self-renewal at the onset of RA-like disease.
To test this hypothesis we have used an Interleukin-1
receptor antagonist knock out mouse model of RA on a
Balb/c background (Balb/c IL1ra-/-), which sponta-
neously develops inflammatory arthropathy with inflam-
matory cellular infiltration, pannus formation and
periarticular bone erosions, similar to RA in humans,
with 100% penetrance by weeks 20 of age [10]. We have
determined the changes present in the bone marrow
microenvironment before disease onset and with devel-
opment of RA-like disease.
This study showed the presence of important changes
occurring in the bone marrow niche before disease
onset in relation to mesenchymal progenitors, adipogen-
esis and osteoclastogenesis. It identifies progressive
amplification of mesenchymal progenitors in the bone
marrow with disease onset and progression but impair-
ment of their differentiation to the osteogenic lineage.
Materials and methods
Reagents and animals
Balb/c and C57BL6 Interleukin-1 receptor antagonist
knock-out mice (Balb/c IL-1ra-/- and C57Bl/6 IL1ra-/-
respectively) and age-matched wild type (WT) controls
were used for the experiments. All animal procedures
were conducted in compliance with institutional and
national guidelines and with ethics committee approval
(PPL 40/2655). Balb/c IL-1ra-/- mice spontaneously
develop chronic inflammatory arthropathy that closely
resembles RA in humans [10]. IL-1ra-/- mice were mon-
itored by visual inspection and mice were sacrificed a)
before disease onset; b) at disease onset identified by the
first visual appearance of swelling and redness of joints;
or c) late disease, characterized by persistent disease
(five weeks from the first sight of joint swelling). In con-
trast C57BL6 IL1 ra-/- do not develop any inflammatory
arthropathy [11] and were used as a further control
group. Bone marrow cells (BMCs) were flushed from
the long bones of mice and used for progenitor assays.
Tibiae were dissected from soft tissue and used for
microCT and histomorphometric analysis.
Progenitor cell assays
Colony Forming Unit-Fibroblasts (CFU-F)
BMCs were plated at the densities of 5 × 105 and 106
cells per well in duplicate in murine-mesenchymal stem
cell complete medium (Stem Cell Technologies, Van-
couver, Canada). The plates were incubated for 14 days
at 37°C in 5% CO2 in air. Colonies were visualized by
Giemsa’s stain solution (VWR, Leicestershire, UK).
Colonies with a minimum of 50 cells were considered as
one CFU-F.
Colony Forming Unit-Osteoblast (CFU-O)
BMCs were plated at a density of 5 × 105 and 106 cells
per well in duplicate in Dulbecco’s modified Eagle med-
ium (DMEM) plus 10% fetal calf serum (FCS) supple-
mented with 100 nM dexamethasone (Sigma Aldrich, St.
Louis, MO, USA), 10 mM b glycerophosphate (Sigma
Aldrich) and 0.05 mM L-Ascorbic Acid (Sigma Aldrich).
Cells were maintained in culture for 14 days and fed
twice a week. Cells were stained for alkaline phosphatase
(ALP) activity using the 86 R alkaline phosphatase kit
(Sigma Aldrich). The colonies comprising at least 20
cells positive for ALP were considered as one CFU-O.
Colony Forming Unit-Adipocyte (CFU-A) by limiting dilution
analysis
BMCs were plated at limiting dilutions (range 105 to
6.25 × 103 cells, eight wells/dilution) in DMEM plus
10% FCS (Hyclone, Fisher Scientific, Loughborough,
UK) in a 96-well culture plate and fed twice a week for
two weeks. After two weeks cultures were supplemented
with Rosiglitazone (5 μM) and cultured at 37°C in CO2
in air for two more weeks. To detect lipid vacuoles cul-
tures were stained for Oil red O as previously described
[12]. This method follows the Poisson distribution and
measures the abundance of cells able to perform a parti-
cular function, in this case to become adipocytes. A well
is considered positive if it contains more than 20 cells
with red lipid vacuoles. The number of CFU-A was cal-
culated using the formula Fo = e-x, where Fo is the frac-
tion of colony-negative wells, e is the constant whose
value is 2.71 and x is the number of colony forming
units per well [13].
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Micro computed tomography (CT)
The tibiae were scanned using a microCT scanner
(model 1172, Skyscan, Aartselaar, Belgium) at 50 kV
and 200 μA with a 0.5 aluminium filter using a detec-
tion pixel size of 4.3 μm. Images were captured every
0.7° through 180° rotation of the bone. The scanned
images were reconstructed using the Skyscan Recon
software and analysed using Skyscan CT analysis soft-
ware. A standard trabecular bone volume of interest was
chosen starting 0.2 mm from the growth plate and
included all the trabeculae in 1 mm3 of bone.
Histological analysis
Tibiae were fixed in 10% neutral buffered formalin, dec-
alcified in EDTA, and embedded in paraffin, and 3 μm
sections were cut using a Leica Microsystems micro-
tome (Leica Microsystems, Milton Keynes, UK). The
sections were stained with either Hematoxylin and
Eosin or Tartrate Resistant Acid Phosphatise (TRAP) to
identify osteoclasts and counterstained with Gill’s hema-
toxylin. The sections were examined by light microscopy
(Leica Microsystems). The number of osteoblasts and
osteoclasts per millimeter were measured on 6.5 mm of
the corticoendosteal surfaces, starting 0.25 mm from the
growth plate using the Osteomeasure analysis software
(Osteometrics, Decatur, GA, USA). Bone marrow adip-
osity was determined by measuring the area occupied by
the adipocytes recognised as white holes defined by the
light blue staining cell wall over 0.75 mm2.
Statistical analysis
All experiments were analyzed using a t-test or a one-
way ANOVA-Dunnett’s post test for multiple compari-
sons. All results are expressed as the mean ± SEM.
Significant P-values were less than 0.05.
Results
Decreased number of bone marrow progenitors with
adipogenic potential and bone marrow adiposity
precedes the onset of RA disease
To determine whether there were changes in bone mar-
row MSC, which preceded the onset of RA-like disease
we determined the number of mesenchymal progenitors
in Balb/c IL1 ra-/- and age matched wild type mice (age
5 to 12 weeks). Balb/c IL1ra-/- mice were sacrificed
when their joints did not show any visual sign of swel-
ling and bone marrow cells were harvested to measure
the number of mesenchymal progenitors. Subsequent
histological analysis of the joints showed a normal syno-
vial membrane with only occasional modest cellular
inflammatory infiltration but no pannus formation or
cartilage and bone erosion (data not shown). No differ-
ence in the number of mesenchymal progenitors (CFU-
F, Figure 1a, n = 8, P = 0.72) and progenitors with
osteogenic potential (CFU-O, Figure 1b, n = 12, P =
0.17) was found in these mice. However, a significant
decrease in the number of progenitor with adipogenic
potential (Figure 1c, CFU-A, n = 8, P < 0.0001) was
detected. This was not uniquely due to the deletion of
the IL1 receptor antagonist gene in this mouse model
because no significant difference in the number of CFU-
A was found in the bone marrow of C57BL6 IL1ra-/-
mice, which have the same genetic deletion but do not
develop RA-like arthritis (Figure 1c, n = 6, P = 0.85).
These data suggest that mice predisposed to develop
RA-like arthritis have a deficiency in mesenchymal
progenitors with adipogenic potential.
To determine if the decrease in mesenchymal progeni-
tors with adipogenic potential resulted in a decrease in
bone marrow adiposity, the percentage of bone marrow
area occupied by adipocytes was determined in Balb/c
IL1ra-/- and compared to age matched wild type con-
trols (age 6 to 14 weeks). As expected this was signifi-
cantly reduced (Figure 1d, n = 9, P = 0.02).
Decreased numbers of activated osteoclasts precede the
onset of RA disease
As adipogenesis and osteogenesis are often inversely
correlated, quantification of bone mass and the number
of osteoblasts was carried out. The number of osteo-
blasts was determined by histomorphometric analysis of
the tibia of Balb/c IL1 ra-/- mice (five to seven weeks of
age) and compared to WT age-matched controls. No
difference in the number of osteoblasts at the endocorti-
cal surface was found (Figure 2a, n = 8, P = 0.17). In
the contrast analysis of a 1 mm3 region of trabecular
bone in the tibia of Balb/c IL1ra-/- mice, carried out by
microCT analysis, an average 23% increase in bone mass
in Balb/c IL1ra-/- mice was revealed when compared to
age-matched WT controls (age 5 to 12 weeks, Figure
2b,c, n = 9, P = 0.01). This was the result of an increase
in trabecular number (3.23 ± 0.14 vs 3.81 ± 0.19 WT vs
Balb/C IL1ra-/-, n = 9, P = 0.03) and not trabecular
thickness (data not shown). To assess that this change
in bone mass was not simply due to the deletion of an
IL1 receptor antagonist gene, C57BL6 IL1ra-/- mice
(aged 11 to 12 weeks), which harbour the same deletion
but do not develop RA-like arthritis, were also analysed.
No significant difference in bone mass was found when
compared to the age-matched WT controls and, if any-
thing, a trend to decrease was observed (Figure 2b, c, n
= 6, P = 0.21). As osteoclasts are responsible for the
resorption of bone, the increase in bone mass is most
likely due to a decrease in the number of activated
osteoclasts. Therefore, the number of TRAP+ osteoclasts
at the endocortical surface was scored and seen to sig-
nificantly decrease (Figure 2d, e, n = 8, P = 0.03). This
was not seen in C57BL6 IL1ra-/- mice (Figure 2d, n = 6,
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P = 0.62). These data suggest that the increase in bone
mass seen in Balb/c IL1 ra-/- is due to decreased
maturation and activation of osteoclasts.
Bone marrow mesenchymal progenitors increase in
numbers with onset and progression of disease
Having seen changes in mesenchymal progenitors before
disease onset and considering that cells with properties
of mesenchymal progenitors have been found increased
in numbers in the synovium of patients affected by RA,
we determined whether mesenchymal progenitors in the
BM were affected by the onset of RA-like arthritis in
Balb/c IL1ra-/- and with progression of the disease. To
achieve this, animals were analysed for the number of
mesenchymal progenitors one and five weeks after iden-
tification of joint swelling by visual inspection. Histology
of the joints was carried out retrospectively to confirm
that signs of inflammation resembling those in RA were
present and matched the visual score (Figure 3). As
expected the histology of ankle joints showed normal
synovial membrane in wild type animals (Figure 3a).
Joints of Balb/c IL1ra-/- mice, which were scored as not
affected by visual inspection also showed a synovial
membrane comparable to wild type animals (Figure 3b).
Figure 1 Decreased bone marrow progenitors with adipogenic potential and adiposity before RA-like disease onset. No significant
difference was found in the number of CFU-F (a) (n = 8) and CFU-O (b) (n = 12) in Balb/c IL-1ra-/- mice when compared to age-matched (age
5 to 12 weeks) wild type mice before disease onset. A significant decrease in CFU-A was found in Balb/c IL-1ra-/- mice (n = 8) but not in C57BL/
6 IL-1ra-/- mice (c) (n = 6) when compared to their respective age matched wild type mice. (d) A representative histological section of tibia
showing absence of adipocytes in the bone marrow of Balb/c IL1ra-/- and representation of the average percentage of bone marrow area
covered by adipocytes in Balb/c IL1ra-/- mice and age matched WT controls (n = 9). Data were analysed by Student t-test. *** P < 0.001. WT,
wild type mice; CFU-F, colony forming unit fibroblast; CFU-O, Colony forming unit osteoblast; CFU-A, colony forming unit adipocyte; BM, bone
marrow; Ad Ar, adipocyte area; BM Ar, bone marrow area; Oc, osteoclasts; Ob, osteoblasts; BV, bone volume; TV, tissue volume. Black arrows
indicate presence of adipocytes.
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Figure 2 Decreased osteoclasts activity precedes the onset of RA disease. (a) No difference in the number of osteoblasts/mm over 6.5 mm
of tibial cortico-endosteal surface in Balb/c IL1ra-/- compared to WT age matched controls before disease onset (n = 8). (b) A representative
example of a horizontal section of tibia after X-ray micro-CT scanning of a Balb/c IL1ra-/- and a C57BL6 IL1ra-/- mouse and respective age
matched WT control. (c) X-ray micro CT scanning of tibia of Balb/c IL1ra-/- mice showed significant increase in bone volume in the cancellous
bone area compared to age matched WT control (n = 9). In contrast, no significant difference was found in C57BL6 IL1ra-/- mouse when
compared to their age matched WT control (n = 6). (d) No significant difference in osteoclast numbers over 6.5 mm of tibial cortico-endosteal
surface was observed in C57BL/6 IL-1ra-/- mice and their age-matched WT controls (n = 6). (e) A representative histological section of tibia
showing decreased number of osteoclasts at the cortico-endosteal surface in Balb/c IL1ra-/- mice compared to WT age matched control and a
graphic representation of the data showing a significant decrease in osteoclast numbers over 6.5 mm of tibial cortico-endosteal surface in Balb/c
IL-1ra-/- mice compared to age matched wild type control mice (n = 8). All data are presented as means ± SEM and analysed by unpaired t-test.
*P < 0.05. WT, wild type mice. Black arrows indicate presence of TRAP+ osteoclasts.
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In contrast, proliferation of synovial cells with significant
inflammatory cellular infiltrations was seen in ankle
joints of Balb/c IL1ra-/- mice sacrificed one week from
visual scoring of joint disease (Figure 3c). These features
became more pronounced with disease progression and
were accompanied by pannus invasion, cartilage damage
and periarticular bone erosion in mice which had the
disease for five weeks as verified from visual identifica-
tion of joint swelling (Figure 3d).
To determine the number of mesenchymal progeni-
tors at the onset of RA-like arthritis, we measured the
number of CFU-F, CFU-A and CFU-O one week after
the visual appearance of redness and swelling of the
joint. As a number of animals developed asymmetric
disease at the knee joints, we compared the number of
progenitors present in the bone marrow of femurs,
which were adjacent (n = 5) or not adjacent (n = 7) to
an inflamed joint, to age-matched wild type controls (15
to 26 weeks of age, n = 7). An increase in CFU-F (Fig-
ure 4a), CFU-O (Figure 4b, c) and CFU-A (Figure 4d)
was seen in IL1ra-/- mice developing the disease. How-
ever, this reached statistical significance only when the
mesenchymal progenitors were contained in the bone
marrow of a femur adjacent to an inflamed joint. This
data suggest that an increase in the number of mesench-
ymal progenitors occurs at the onset of RA-like arthritis
but is more prominent in the bone marrow adjacent to
an inflamed joint.
To determine whether the number of progenitors sig-
nificantly increased independently of the site of inflam-
mation with disease progression, femurs not adjacent to
the site of inflammation were analysed five weeks after
visual appearance of swelling of the ankle joints (age 14
to 23 weeks). A significant increase in the number of
CFU-F (Figure 5a, n = 8, P = 0.001) and CFU-O (Figure
5b, n = 8, P = 0.01) was observed independent of the
site of inflammation. No significant increase was
observed when comparing the number of CFU-A (Fig-
ure 5c, n = 8, P = 0.15). However, considering that
Balb/c IL1ra-/- mice showed a significantly reduced
number of CFU-A before disease onset, the data indi-
cated an overall increase in the number of CFU-A in
the bone marrow of Balb/c IL1ra-/- as a result of the
disease. These data suggest that with disease progression
the number of mesenchymal progenitors increase inde-
pendent of the site of inflammation.
Figure 3 The disease visual score correlates with histological changes in the affected joints. (a) A representation of ankle joint in wild
type mouse at 10 weeks of age showing no evidence of synovitis or bone erosion; (b) A representation of a non-inflamed ankle joint in Balb/c
IL1ra-/- mouse at 10 weeks of age showing no evidence of synovitis and bone erosion; (c) A representation of inflamed ankle joint in Balb/c
IL1ra-/- one week after appearance of visual swelling of the joint demonstrating extensive infiltration of the synovium by inflammatory cells and
pannus, like synovial proliferation but no bone erosion; (d) A representation of inflamed ankle joint in Balb/c IL1ra-/- mouse affected by swelling
of the ankle for five weeks as determined by visual inspection, showing synovitis and erosion of bone by osteoclasts (Oc) within the pannus-like
synovial proliferation. Black arrows indicate synovium, * joint surface, a continuous black line demonstrates the interface between the synovium
and bone and joint surfaces. All figures are of haematoxylin and eosin-stained paraffin-embedded sections, original magnifications ×200.
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Block in osteoblast differentiation with disease
progression
To determine whether an increase in mesenchymal pro-
genitors, particularly progenitors with osteogenic poten-
tial, translated into an increase in the number of
osteoblasts and bone mass, these were analysed by histo-
morphometry and microCT analysis. No significant dif-
ference was found in the number of osteoblasts at
disease onset (23.2 ± 3.2 vs 18 ± 4.1 N Ob/mm, WT vs
Balb/c IL1ra-/- respectively, n = 6, P = 0.71). Interest-
ingly, when mice had the disease for five weeks the
number of osteoblasts decreased and this was more pro-
nounced in older mice (Figure 6a, 31 to 32 weeks old,
n = 3, P = 0.039) compared to younger mice (Figure 6a,
22 to 23 weeks old, n = 5, P = 0.07). To determine
whether the decrease in osteoblasts translated into a
decrease in bone mass, micro CT analysis was carried
out and showed no significant difference when compar-
ing the tibia of Balb/c IL1ra-/- to wild type age-matched
mice (15 to 26 weeks of age) at the onset of RA-like
arthritis (2.7 ± 0.8 vs 2 ± 0.6, WT vs Balb/c IL1ra-/-,
n = 8, P = 0.14) or with disease progression (Figure 6b,
n = 8, P = 0.50, age 22 to 32 weeks old). Adjacency of
the site of inflammation to the analysed tibia did not
have any influence on bone mass (data not shown).
As osteoclasts were significantly decreased in Balb/c
IL1ra-/- before the start of RA-like arthritis and they are
known to be increasingly activated in the joint of
patients affected by RA we determined whether the
number of activated osteoclasts was affected by the
disease onset and progression. No significant difference
in osteoclasts numbers was found at disease onset (1.3 ±
0.2 vs 1 ± 0.3 N Oc/mm, WT vs Balb/c IL1ra-/- respec-
tively n = 6, P = 0.36) or with disease progression in
Balb/c IL1ra-/- mice at 22 to 23 weeks of age (Figure
6c, n = 5, P = 0.54) or 31 to 32 weeks of age (Figure 6c,
n = 3, P = 0.19) compared to age-matched wild type
controls. However, as IL1ra-/- mice showed a decreased
number of osteoclasts before disease onset, this suggests
a change in the activation profile of osteoclasts with dis-
ease establishment. Activated osteoclasts are no longer
decreased in number compared to wild type mice and, if
anything, a trend to increase is seen. Similarly the
increase in bone mass seen before disease onset is also
lost with disease establishment. This, together with a
block in differentiation of the mesenchymal progenitors
with osteogenic potential to the osteoblast lineage, sug-
gests an overall accelerated bone loss in Balb/c IL1 ra-/-
with disease onset and progression.
Discussion
The role of the bone marrow niche and mesenchymal
stem cell in haemopoiesis and regulation of inflamma-
tion is becoming progressively recognised [14-16].
Despite the fact that in RA there are clearly defined dis-
turbances in the haemopoietic and immune system,
changes in bone marrow mesenchymal stem cells and
their progeny, which may drive those modifications,
have not been studied. To address this question we have
used the IL1ra-/- on a Balb/c background. This model
Figure 4 Increase in bone marrow mesenchymal progenitors at the onset of RA-like disease. A significant increase in BM-MSC (a),
progenitors with osteogenic (b-c) and adipogenic (d) potential was found in Balb/c IL-1ra-/- mice compared to WT controls at the onset of
disease (n = 5 with disease in adjacent joint, n = 7 with disease in non-adjecent joint). (b) is a representative example of CFU-O cultures from
bone marrow cells of Balb/c IL1ra-/- mice affected by RA and age matched WT control. All data are presented as means ± SEM and analysed by
one way ANOVA and Bonferroni post-test. *P < 0.05, **P < 0.01, ***P < 0.001. WT, wild type mice; CFU-F, colony forming unit fibroblast; CFU-O,
colony forming unit osteoblast; CFU-A, colony forming unit adipocyte; BM, bone marrow.
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Figure 5 The increase in mesenchymal progenitors is
independent of the site of inflammation with disease
progression. (a) A significant increase in the number of CFU-F,
independent of the proximity to an inflamed joint, was found in the
bone marrow of Balb/c IL-1ra-/- mice compared to WT controls
with disease progression (n = 8). A significant increase in the
number of progenitors with osteogenic (b) (n = 8) and adipogenic
(c) (n = 8) potential in the bone marrow not adjacent to an
inflamed joint in Balb/c IL1 ra-/- mice compared to WT age
matched controls. Mice showed signs of RA-like disease for five
weeks. All data are presented as means ± SEM and analysed one
way ANOVA and Bonferroni post-test. *P < 0.05, **P < 0.01, ***P <
0.001. WT, wild type mice; CFU-F, Colony Forming Unit - Fibroblast;
CFU-O, Colony Forming Unit - Osteoblast; CFU-A, Colony Forming
Unit - Adipocyte; BM, bone marrow.
Figure 6 Decreased osteoblast differentiation is progressive
with disease development and age of the mice. (a) A
representative example of histological section of osteoblasts at the
tibial endo-cortical surface of Balb/c IL1ra-/- (32 to 33 weeks old)
compared to WT age-matched control mice. A decrease in the
number of osteoblasts over 6.5 mm of tibial endo-cortical surface in
Balb/c IL1ra-/- affected by the disease for five weeks was observed
and was found more prominent in older mice (aged 31 to 32
weeks, n = 3) than younger mice (aged 22 to 23 weeks, n = 5)
despite they both had the disease for the same length of time. (b)
X-ray micro CT scanning of tibia of Balb/c IL1ra-/- mice showed no
significant difference in bone volume in the cancellous bone area
with disease progression (n = 8). (c) No significant difference in
osteoclast numbers was observed with the progression of disease in
Balb/c IL1ra-/- mice which were 22 to 23 weeks of age (n = 5) or 31
to 32 weeks of the age (n = 3) compared to age matched WT
control mice. All data are presented as means ± SEM and analysed
by unpaired t test. *P < 0.05. WT, wild type mice; BV/TV, bone
volume/tissue volume; Oc, osteoclasts; Ob, osteoblasts.
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has histopathological features, which closely resemble
arthritis present in patients affected by RA with synovi-
tis, inflammatory cellular infiltration, which includes
lymphocytes, pannus formation and periarticular bone
erosions. The knocking out of the interleukin-1 receptor
antagonist is permissive but not solely responsible for
the occurrence of RA-like arthropathy as the occurrence
depends also on the mouse strain. Moreover, the histo-
pathological features of the disease differs from those
described in patients who harbour a deletion of the
interleukin-1 receptor antagonist gene recently described
[17]. In those patients there is multiple chronic osteo-
myelitis, and bone erosions are intraosseous and not
periarticular as seen in our murine model or in patients
affected by RA. Therefore, the Balb/c IL1ra-/- is a valu-
able model to study events which occur over time and
in the BM. Obtaining BM samples from patients
affected by RA and who have not undergone treatment
is difficult.
Here, for the first time, we provide evidence of
changes in the composition of the bone marrow niche
present already before the development of RA-like dis-
ease. We have shown a deficiency in mesenchymal pro-
genitors with adipogenic potential and bone marrow
adiposity together with a decrease in the maturation of
osteoclasts before disease development. Moreover, this
was present only in Balb/c IL1 ra-/- mice, who pro-
gressed to develop RA-like disease and not in C57BL6
IL1ra-/-, which have been shown not to develop RA-like
arthritis, suggesting an association of these abnormalities
with RA development. Although it is difficult to predict
the precise cascade of events leading from low adipo-
genesis to decreased activation of osteoclasts, there is
evidence that the two processes may be linked. Mature
adipocytes release adipokines such as leptin, ghrelin and
adiponectin, or growth factors such as monocytes che-
motactic protein 1 (MCP-1) [18]. For examples, MCP-1
has been shown to mediate osteoclastogenesis and bone
resorption [19]. Further studies are now needed to
understand the genetic alterations and the cascade of
events leading to those abnormalities.
Regardless of the precise cascade of events, our data
are in agreement with other published data. In the study
by Naivares et al (2009) low bone marrow adiposity has
been positively correlated with the ability to support
proliferation of hematopoietic progenitors [8]. Lack of
adipogenesis in AZIP/F1 recipient mice (genetically
incapable of forming adipocytes) enhanced hematopoie-
tic recovery after lethal irradiation by enhancing engraft-
ment of short term progenitors [8]. Adipocyte-rich
marrow was shown to harbour a decreased frequency of
progenitors and relatively quiescent stem cells [8].
Therefore the reduction in adipogenesis in Balb/c
IL1ra-/- mice supports the notion of an enhanced
stimulation of the HSC to proliferate and is in agree-
ment with the study by Schonland et al. (2003) where
individuals with the HLA-DRB104 haplotype, shown to
be more at risk for developing rheumatoid arthritis, had
accelerated telomere shortening of both lymphocytes
and neutrophils, a marker of cellular proliferation and
ageing of haemopoietic progenitors [4].
Dysregulated adipogenesis may be responsible for the
establishment of a proinflammatory environment. Adi-
ponectin has been suggested to have a role in vivo for
immediate moderation of inflammatory reactions occur-
ring after invasion by foreign pathogens and prevents an
excessive and prolonged inflammatory response. Indeed
lipopolysaccharide (LPS) induced expression of TNFa
mRNA in macrophages and was markedly suppressed
by pre-treatment with recombinant adiponectin [20].
Adiponectin pre-treated macrophages failed to release
TNF-a in response to LPS [20]. Therefore it is not
unreasonable to suggest that the low number of adipo-
cytes found in the bone marrow of Balb/c IL1ra-/- mice
may lead to reduced levels of adipokines, such as adipo-
nectin, which in turn reduce activation of macrophages
and allows increased presence of inflammatory cytokines
such as TNF-a, following the start of any inflammatory
process. Indeed, elevated levels of TNFRII, a surrogate
soluble receptor, which parallel levels of TNF-a, has
been found elevated in the preclinical phase of disease
of patients that go on to develop RA up to eight years
after [21].
MSC share many properties with fibroblast-like syno-
viocytes (FLS) [22], the cells responsible for the thicken-
ing of the synovium in the joint in RA and perpetuation
of the inflammatory process by recruiting and support-
ing the survival of inflammatory cells [23]. It is thought
that MSC may even contribute to the FLS pool in the
joint. When the bone marrow of green fluorescence pro-
tein (GFP) transgenic donor mice was transplanted into
lethally irradiated recipient mice, it was shown that nor-
mal FLS contained a minor fraction (1.2%) of GFP+
cells [24]. As FLS undergo increased proliferation it is
not unreasonable to suggest that MSC may undergo
expansion in the bone marrow too at disease onset and
change the composition of the bone marrow niche. Our
data point to increased numbers of MSC following
establishment of the disease. Our findings are not in
agreement with a previous study measuring the number
of bone marrow mesenchymal progenitors in patients
affected by RA, where no significant difference was
found [25]. The reason for the apparent discrepancy
may lie in the fact that most patients included in the
study by Kastrinaki et al. (2008) [25] had undergone
treatment and those who had not undergone treatment
were a very small number with a wide age range. This
may have compromised the detection of any difference,
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especially considering that the number of CFU-F tend to
decrease with age [12].
Of interest is the accumulation of progenitors, which are
unable to differentiate to the osteoblast lineage. The
mechanism leading to MSC accumulation and blocking of
their differentiation are unclear and likely due to a com-
plex interplay of cytokines and cellular cross talks, mostly
related to the in vivo inflammatory environment. When
these cells were induced to differentiate to the osteoblast
lineage in vitro they showed formation of colony forming
unit-osteoblasts, which were alkaline phosphatase positive
and did not differ in the pattern of staining from those
derived from the bone marrow of their wild type age-
matched controls. Proinflammatory cytokines such as
TNF-a and IL1b have been shown to block osteogenic dif-
ferentiation in vitro [26,27] and support our findings. The
accumulation of MSC, known to secrete RANKL, may
also lend an explanation to the loss of defective osteoclas-
togenesis observed in the Balb/c IL1ra-/- animals before
disease onset. Indeed, our data shows that with the estab-
lishment of disease the number of osteoclasts is no longer
significantly decreased and, if anything, it exhibits a trend
to increase. This is in agreement with the well-known
increase in the number of activated osteoclasts reported in
the joints of patients with RA and with data suggesting
that at very early stages of inflammation, when levels of
TNF-a are low, mesenchymal stem cells are required for
osteoclastogenesis [28]. All together our data are in agree-
ment with reports of RA patients developing systemic
osteoporosis with time [29] and of systemic accelerated
bone loss in another model of inflammatory arthritis
mainly as the result of arrested osteoblast function [30].
Ways to induce effective differentiation of the mesenchy-
mal progenitors to the osteoblast lineage may provide
both a way to reduce expansion of MSC and prevent
systemic bone loss.
The accumulation of MSC raises the intriguing ques-
tion whether these cells, known for their immunosup-
pressive properties, are exerting the expected anti-
inflammatory action and whether the proposed adminis-
tration of additional MSC, as novel therapeutic strategy
in RA, would have the desired effect of dampening the
auto-immune responses. Despite a wealth of literature
describing the immunosuppressive ability of MSC, more
recently a pro-inflammatory phenotype of MSC has also
been described [31,32]. This requires activation of TLR4
and possibly TLR3 receptors present on MSC. Indeed
overexpression of TLR3 and TLR4 has been described
in synovial fibroblasts of patients affected by RA and
beg the question whether bone marrow mesenchymal
stem cells in RA patients show similar overexpression
and have a pro-inflammatory phenotype as a result of
their engagement [33]. The fact that administration of
murine MSC in models of RA disease has given
contrasting results [34,35] highlights that this is a poten-
tial problem and calls for a closer analysis of the inflam-
matory phenotype of the patients’ MSC at the time of
active disease, following expansion before administration
and after administration to the patient. This may help
to determine whether MSC preparation varies in terms
of predisposition to acquire a pro-inflammatory pheno-
type or whether this is an acquired characteristic as a
result of contact with the patients’ cellular environment.
Moreover, it may establish whether the cellular environ-
ment confers the pro-inflammatory phenotype depend-
ing on the disease stage and status of remission.
Conclusions
We have shown an accumulation of MSC progenitors
with the onset of RA-like disease and a block in their
differentiation to osteoblasts. These data highlight the
need for therapeutic intervention with molecules capable
of inducing differentiation of MSC to osteoblasts to pre-
vent the onset of osteoporosis. Moreover, it puts into
question whether additional administration of MSC pro-
posed as treatment to reduce the autoimmune response
[30] is required and would be efficacious. More studies
into the molecular mechanism leading to enhanced
maintenance of MSC in RA-like disease, their pro-
inflammatory phenotype and ways to interferes with this
are required. Small molecules such as glycogen synthase
kinase -3 inhibitors have been shown to have anti-
inflammatory properties and to drive commitment of
MSC to osteogenic lineage [36,37], suggesting they may
have a therapeutic impact in both reducing inflamma-
tion and bone loss.
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